peloswing Posted - 4 days ago

Monday: The two-day Stifel Healthcare Conference will include participation from a large number of companies in the healthcare sector, including: Johnson & Johnson $JNJ Editas Medicine $EDIT Merus N.V. $MRUS Qiagen $QGEN Ionis Pharmaceuticals $IONS And others...

JamesWooster390 Posted - 6 days ago

$QGEN Industry advancements are a wake-up call for KSCP to prioritize leadership in tech innovation.

Estimize Posted - 1 week ago

Wall St is expecting 0.60 EPS for $QGEN Q4 [Reporting 02/11 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co

swingingtech Posted - 1 week ago

$QGEN $NUE $SNDX https://wallstreetwaves.com/significant-tuesday-options-trading-insights-qgen-nue-sndx/

DonCorleone77 Posted - 2 weeks ago

$QGEN Qiagen raises FY24 adjusted EPS view to $2.19 from $2.10, consensus $2.15 Backs FY24 revenue view $1.99B, consensus $1.98B. "Our 2024 results to date reflect a positive quarterly trend in sales and adjusted earnings, along with a 73% increase in free cash flow. We are well-positioned to achieve the updated outlook for 2024 as we once again increase our adjusted EPS target," said Roland Sackers, CFO of Qiahen. "We are implementing initiatives to simplify QIAGEN and increase efficiency, and these initiatives are putting us on track to increase our adjusted operating income margin above 31% by the end of 2028, reaffirming our commitment to solid profitable growth."

DonCorleone77 Posted - 2 weeks ago

$QGEN Qiagen reports Q3 adjusted EPS 57c, consensus 54c Reports Q3 revenue $502M, consensus $491.74M. "QIAGEN delivered another solid performance in the third quarter of 2024, exceeding our goals for net sales and adjusted earnings thanks to the strong trends in our business and the resilience of our portfolio with over 85% of sales from highly recurring revenues. We are executing quarter after quarter in this challenging macro environment on delivering sales growth combined with market share gains and operational efficiency thanks to a differentiated portfolio," said Thierry Bernard, CEO of Qiagen.

DonCorleone77 Posted - 2 weeks ago

$QGEN Qiagen announces FDA clearance for QIAstat-Dx Meningitis/Encephalitis Panel Qiagen announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use. This marks the fourth QIAstat-Dx syndromic test to receive U.S. regulatory clearance in 2024.

swingingtech Posted - 10/29/24

$EYPT $QGEN https://wallstreetwaves.com/eyepoint-pharmaceuticals-eypt-rallies-27-6-whats-next-for-the-stock/

DonCorleone77 Posted - 10/29/24

$QGEN Qiagen announces FDA clearance of QIAstat-Dx Respiratory Panel Mini test Qiagen announced that the FDA has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper respiratory infections in outpatient settings and covers five common viral causes of illness: influenza A, influenza B, human rhinovirus, respiratory syncytial virus and SARS-CoV-2.

Estimize Posted - 10/28/24

Wall St is expecting 491.20 revenue for $QGEN Q3 [Reporting 11/06 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=reve

themacromindset Posted - 1 month ago

$QGEN QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology $QGEN

DonCorleone77 Posted - 09/26/24

$QGEN Qiagen gets European IVDR certification The company states: "QIAGEN announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation, or IVDR. This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement underscores QIAGEN's commitment to meeting the highest standards of safety, quality, and performance, as it has already transitioned 80 percent of over 180 products to the new regulatory framework. The new IVD regulation aims to ensure the safety, quality and effectiveness of in-vitro diagnostic devices, overseen by independent organizations in the EU known as Notified Bodies. Devices are now classified by risk level, from Ato D. The QIAstat-Dx instruments, QIAstat-Dx Analyzer 2.0 and QIAstat-Dx Rise, are classified as Class A devices, while the QIAstat-Dx Gastrointestinal Panel 2 is classified as a Class C device. The QIAstat-Dx Respiratory Panel Plus is classified as a Class D device - the highest risk category - highlighting QIAGEN's capabilities to meet highest regulatory thresholds in Europe. The submission for IVDR certification of the QIAstat-Dx Meningitis/Encephalitis Panel is expected in the coming months."

Stock_Titan Posted - 09/26/24

$QGEN QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays https://www.stocktitan.net/news/QGEN/qiagen-receives-european-ivdr-certification-for-qi-astat-dx-eepp6a79zsfh.html

DonCorleone77 Posted - 09/23/24

$QGEN Qiagen, Bode team to advance GEDmatch PRO forensic genealogy database Qiagen announced "that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data." The multi-year agreement between QIAGEN's subsidiary Verogen and Bode extends the long-standing partnership of two leading companies in forensic investigative genetic genealogy or FIGG, to further accelerate the use of GEDmatch PRO in law enforcement and identification of human remains. QIAGEN has been providing GEDmatch PRO to customers since the early 2023 acquisition of its subsidiary Verogen, a proven leader in equipping forensic science laboratories and criminal investigators to use next-generation sequencing,NGS, to gain deeper insights...As part of the partnership, Bode will manage all commercial transactions for GEDmatch PRO globally, while QIAGEN will continue to develop new features with input from Bode's genealogy experts. Bode will maintain the highest level of data security as GEDmatch PRO users will continue to own their case data and no additional identifying information will be shared with Bode. QIAGEN's subsidiary will continue to have sole responsibility and manage the separate GEDmatch consumer database and its free DNA comparison-and-analysis website, which are not affected by this partnership.

Stock_Titan Posted - 2 months ago

$QGEN QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform https://www.stocktitan.net/news/QGEN/qiagen-expands-qi-acuity-digital-pcr-offering-with-over-new-100-fgej53ltm3df.html

DonCorleone77 Posted - 2 months ago

$QGEN Qiagen and Bio-Manguinhos/Fiocruz collaborate to enhance malaria screening Qiagen announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinhos is now able to launch an advanced PCR-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, HCV and HBV, a capability previously unavailable in Brazil's blood donation program. It also supports epidemiological surveillance of Brazil's ongoing dengue epidemic by composing Bio-Manguinhos/Fiocruz dengue molecular kits based on unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz. QIAGEN will supply critical molecular biology technologies, custom solutions, and comprehensive training to facilitate Brazil's public health initiative. Initiated in 2010, this is the largest blood donation safety initiative in the country's history.

Genesis206 Posted - 2 months ago

$LLY today alone, its weekly insulin replacement beat traditional daily treatments in testing, signed a research deal with Genetic Leap and announced an Alzheimer’s partnership with $QGEN and is down 3.6%… that’s opportunity.

Stock_Titan Posted - 2 months ago

$QGEN QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease https://www.stocktitan.net/news/QGEN/qiagen-and-lilly-collaborate-to-support-development-of-a-qi-astat-dx-y84bkp2r4lq7.html

Stock_Titan Posted - 08/28/24

$QGEN QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases https://www.stocktitan.net/news/QGEN/qiagen-expands-qi-astat-dx-into-precision-medicine-through-y1wejf5udvq4.html

jjmstocks1 Posted - 08/27/24

$QGEN +2% YTD .. assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research .. these are a shade under the 10-day + nice job of finishing the session inside ..

THEvigilante Posted - 3 months ago

$UVXY $QGEN $SNY Take this as a sign that I may have a crystal ball 🔮 If my intuition proves correct, QGEN & SNY will be going up like Moderna did with COVID…you can thank me later 💰 https://thehill.com/opinion/4810909-bird-flu-factory-farms-risk/amp/

Jodah Posted - 3 months ago

$QGEN 🚀

G101SPM Posted - 3 months ago

$QGEN $44.42 SELL/ TALK PROFIT. DAC $41.81 (12.7.23). See prior post.

G101SPM Posted - 3 months ago

$QGEN $44.69 bid. DAC (dollar average cost) $41.81 (12.7.23). *EXIT $55.00 (prior). UPDATE: Reports Q2 (Jun) earnings of $0.55 per share, $0.03 better than consensus of $0.52; revenues fell 0.2% year/year to $496 mln vs the $495.45 mln. Co issues mixed guidance for FY24, sees EPS of $2.16, vs. $2.12; sees FY24 revs of at least $1.985 bln vs. $2.00 bln. * Plan to liquidate this morning on weaker SPM tag.

epsguid Posted - 07/31/24

$QGEN reported earnings of $0.55, consensus was $0.52, Earnings Whisper was $0.53 via @eWhispers #whisperbeat http://eps.sh/d/qgen

DonCorleone77 Posted - 07/31/24

$QGEN Qiagen ups FY24 adjusted EPS view to at least $2.16 from $2.14, consensus $2.12 "QIAGEN again delivered growth ahead of our outlook for the second quarter of 2024 that gives us renewed confidence in achieving the updated outlook for sales and adjusted earnings for 2024," said Roland Sackers, Chief Financial Officer of QIAGEN. "We are seeing the benefits of our initiatives to improve profitability, as we confirm our full-year target for an adjusted operating income margin of at least 28.5%, combined with higher free cash flow. These improvements put us on a trajectory to achieve the targets we have set for 2028 as part of our commitment to solid profitable growth."

DonCorleone77 Posted - 07/31/24

$QGEN Qiagen reports Q2 adjusted EPS 55c, consensus 51c Reports Q2 revenue $496M, consensus $494.49M. "Our teams executed well in the second quarter, showing sequential growth from the first quarter as well as over the year-ago period as we accelerate our performance during 2024. We are on track to achieve our updated outlook that reflects the strong trends in our core business along with the decision on the NeuMoDx system," said Thierry Bernard, CEO of QIAGEN.

Stock_Titan Posted - 07/31/24

$QGEN QIAGEN delivers solid performance and exceeds outlook for Q2 2024 https://www.stocktitan.net/news/QGEN/qiagen-delivers-solid-performance-and-exceeds-outlook-for-q2-ek9wdzum597k.html

G101SPM Posted - 07/24/24

$QGEN $41.89 bid. DAC $41.81 (12.7.23). CHANGE EXIT TO $55.00 FROM $48.00. OVERVIEW: Company plans to to deliver solid profitable growth through 2028 -- led by about 7% compound annual sales growth (CAGR) at constant exchange rates (CER) during the four-year period and achieving at least a 31% CER adjusted operating income margin in 2028. QIAGEN's leadership team will present the new 2028 targets, highlighting QIAGEN's vision and strategy to sharpen its focus on growth pillars in the portfolio combined with commitments to solid profitable growth and disciplined capital allocation. This includes plans to return at least $1 billion to shareholders from 2024-2028, absent value-creating M&A opportunities, along with a high level of organic business investments. QIAGEN has set a goal for at least $2 billion of combined annual sales in 2028 from its pillars amid plans for new product launches and important investments. note: EA7.31 --- earnings release.

Stock_Titan Posted - 4 months ago

$QGEN QIAGEN to enhance the identification of human remains of Indigenous people and African Americans https://www.stocktitan.net/news/QGEN/qiagen-to-enhance-the-identification-of-human-remains-of-indigenous-h1g7lysza7cy.html